Login or sign up
For business

Allogene therapeutics

3.9Β· 11 reviews
Average ratingAverage
3.9/ 5

Based on 11 reviews

527%
436%
336%
20%
10%
Ask AI

Ask AI about Allogene therapeutics

Generated with AI from 11 reviews on Trustburn

AI-generated from reviews on this page. Verify anything important with the company directly.

Jeno Blenessy
Reviews 1

I am a satisfied customer of Allogene therapeutics. The company is doing a great job in developing innovative cancer therapies. I am impressed with their commitment to patient care and their dedication to advancing the field of cell therapy. Their website, allogene.com, is informative and user-friendly.

Babu Thomas
Reviews 1

Allogene therapeutics is a company that truly cares about patients. Their innovative cancer therapies have the potential to make a significant impact in the lives of cancer patients. I appreciate their dedication and commitment to advancing the field of cell therapy. πŸ‘

Robin Vanzandt
Reviews 1

🌟 I am extremely impressed with Allogene therapeutics and their work in developing innovative cancer therapies. The company's dedication to improving patient outcomes is commendable. The website, allogene.com, is a valuable resource for anyone seeking information on their therapies. πŸ™Œ

News

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying a widget on your website β€” a simple way to convert your visitors into customers.

Get the widget for your site →

About Allogene therapeutics

Allogene Therapeutics is a clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.

Address
210 east grand avenue
Categories
Biotechnology